Surya Pharmaceutical Peer Comparison

NSE: SURYAPHARM | BSE: 532516

₹0.16

₹-0.01 (-5.88%)

As on 14-Sep-2015IST

Market cap

₹3 Cr

Revenue (TTM)

₹3 Cr

P/E Ratio

P/B Ratio

-0

Div. Yield

0 %

Edit

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	3	31,878	30,554	28,624	27,296
Revenue (₹ Cr)	3	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	258.68	414.00	288.22	-371.81	387.35
Net Margin (%)	9,933.76	11.23	14.79	-3.93	26.01
RoE (%)	--	8.38	29.77	-3.85	25.18
Price to Earnings	0.01	77.94	106.01	--	70.67
Price-To-Book	0.00	6.33	22.76	3.58	15.79

Income Statement (₹ Cr)

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	90.44	5,609.42	37.09	--	55.51
Total Income	91.42	5,663.42	37.09	--	55.99
Total Expenditure	273.11	3,549.74	27.46	--	50.88
EBITDA	-182.67	2,059.68	9.63	--	4.63
Depreciation	68.35	122.14	3.08	--	0.90
EBIT	-251.01	1,937.54	6.55	--	3.73
Interest	221.61	215.37	2.58	--	1.11
Other Income	0.97	54.00	--	--	0.47
Exceptional Items	-17.93	61.52	--	--	--
Profit before Tax	-489.58	1,837.69	3.97	--	3.09
Provision for Tax	-156.90	258.21	1.13	--	1.04
Profit after Tax	-332.68	1,579.48	2.84	--	2.05

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	-78.39	2,704.18	40.33	--	8.16
Minority Interest	-15.52	--	--	--	--
Non-Current Liabilities	147.64	1,520.80	7.33	--	1.19
Current Liabilities	1,840.35	1,773.48	21.75	--	16.97
Total Liabilities	2,149.37	6,022.66	69.41	--	26.51

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	902.94	2,671.53	49.55	--	5.37
Current Assets	991.13	3,326.93	19.86	--	20.95
Total Assets	2,149.37	6,022.66	69.41	--	26.51
Total Debt*	2,171.17	2,070.47	19.09	--	8.17
Net Current Assets	-849.22	1,553.45	-1.89	--	3.98
Contingent Liabilities	266.85	79.85	0.70	--	--

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	133.21	1,532.40	3.99	--	--
Cash Flow from Investing Activities	-7.95	1,085.37	-4.09	--	--
Cash from Financing Activities	-133.12	-2,245.75	0.43	--	--
Net Cash Inflow / Outflow	-7.86	372.02	0.33	--	0.00

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-12.70	42.17	11.29	--	29.13
ROE (%)	-451.80	102.78	14.27	--	28.77
ROA (%)	-16.34	25.78	4.14	--	8.50
EBIT Margin (%)	-200.89	37.68	25.96	--	9.19
Net Margin (%)	-363.91	27.89	7.66	--	3.67
Cash Profit Margin (%)	-279.02	30.30	15.96	--	4.96

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	-94.83	28.94	6.60	--	63.77
EBIT Growth (%)	12.25	53.27	5.26	--	21.99
Net Profit Growth (%)	-9.15	427.46	12.54	--	52.02
EPS Growth (%)	-5.01	364.85	12.54	--	52.02
Book Value Growth (%)	-135.41	239.42	15.36	--	33.62

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	12.71	0.00	--	0.00
Price / Book Value	-0.35	9.26	0.00	--	0.00
Dividend Yield (%)	0.00	0.25	--	--	--
EV/EBITDA	-12.06	11.00	4.10	--	1.79
Market Cap (₹ Cr)	28.53	21,979.56	0.00	--	0.00

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	-26.89	0.77	0.47	--	1.00
Short term debt to equity ratio	-21.22	0.07	0.24	--	0.67
Current Ratio	0.54	1.88	0.91	--	1.23
Quick Ratio	0.19	1.28	0.85	--	0.87
Interest Coverage	-1.21	9.53	2.54	--	3.77

	Surya Pharmaceutical	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	249.68	17.09	27.75	--	19.50
Asset Turnover	0.05	0.92	0.54	--	2.47
Receivable days	917.33	55.81	123.43	--	58.39
Inventory Days	2,833.48	63.29	10.53	--	37.68
Payable days	101.21	122.70	--	--	93.41
Cash Conversion Cycle	3,649.60	-3.60	--	--	2.66

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.